Clinical Trial Update: AK105 Combined With Anlotinib in Patients With Cervical Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial exploring AK105 in combination with Anlotinib for cervical cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• AK105 (anti-PD-1 monoclonal antibody)
• Anlotinib (anlotinib)

Snippet

Sponsor: The First Affiliated Hospital of Zhengzhou University | Conditions: Cervical Cancer | Phase 2 | Status: UNKNOWN